Constellation Pharmaceuticals (NASDAQ:CNST) is advancing lead candidate CPI-1205 into the Phase 2 portion of its Phase 1/2 study, ProSTAR, in metastatic castration-resistant prostate cancer. The study will assess CPI-1205 plus Pfizer's (NYSE:PFE) Xtandi (enzalutamide) compared to enzalutamide alone in a first-line setting.
It is also adding a new arm evaluating the combination of CPI-1205 and Johnson & Johnson's (NYSE:JNJ) Zytiga (abiraterone acetate) in patients who progressed after enzalutamide (second-line setting).
Now read: Johnson & Johnson's Real Value »
Subscribe for full text news in your inbox